Crinetics Pharmaceuticals, Inc. (CRNX) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Crinetics is a pharmaceutical company focused on endocrine diseases and tumors. Its lead commercial product, PALSONIFY (paltusotine), was launched in the U.S. in late 2025 and received EMA approval in April 2026. The company is also advancing atumelnant for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome (ADCS).
Material Subsequent Event: On July 6, 2026, Crinetics entered into a definitive Merger Agreement to be acquired by Vertex Pharmaceuticals Incorporated for $85.00 per share in cash. The transaction is expected to close in Q3 2026, subject to shareholder approval and regulatory clearances.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $35,852 |
| Product Revenue (PALSONIFY) | $34,344 |
| Collaboration & License Revenue | $1,508 |
| Net Loss | $(248,700) |
| Net Loss Per Share (Diluted) | $(2.37) |
| Operating Cash Flow | $(218,896) |
| Cash, Cash Equivalents & Investments | $1,205,773 |
| Working Capital | $1,164,447 |
| Accumulated Deficit | $(1,666,127) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased to $35.9 million from $1.4 million in the prior year period, driven entirely by the commercial launch of PALSONIFY. Product revenue grew sequentially from $10.3 million in Q1 2026 to $24.0 million in Q2 2026.
- Expense Increases: Operating expenses rose to $308.7 million (vs. $241.9 million YoY).
- R&D: Increased to $199.9 million, primarily due to higher clinical trial and manufacturing costs for atumelnant.
- SG&A: Increased to $108.4 million, reflecting commercial infrastructure build-out and transaction-related costs for the Vertex merger.
- Liquidity: Cash and investment balances increased by $177.9 million compared to year-end 2025, bolstered by a $380 million equity offering in January 2026.
Outlook, Risks, and Management Commentary
- Merger Status: The company is operating under the Merger Agreement with Vertex. Shareholders will receive $85.00 per share in cash. The deal is not subject to a financing condition but requires shareholder approval and regulatory clearance (HSR Act).
- Commercial Progress: PALSONIFY showed strong uptake in Q2 2026 with 245 enrollment forms and 385 unique prescribers. Over 70% of patients were on reimbursed therapy.
- Pipeline Updates:
- Atumelnant: Phase 2/3 EQUILIBRIUM study for ADCS expected to randomize first participant in H2 2026.
- SKK License: SKK submitted an NDA in Japan for paltusotine in April 2026.
- Risks:
- Merger Termination: If the Merger is terminated under specific circumstances (e.g., superior proposal), Crinetics may owe a termination fee of approximately $350.5 million.
- Operational Restrictions: The company is restricted from pursuing alternative transactions or making significant changes to its business during the pendency of the Merger.
- Liquidity: While current resources are sufficient for 12+ months, the company expects to continue incurring net losses and may require additional capital if the Merger does not close or if commercialization costs exceed expectations.
Investor Verification Checklist
- Merger Closing Conditions: Verify the status of shareholder approval and regulatory clearances (HSR Act, foreign regulators) required to close the Vertex transaction.
- Termination Fee Exposure: Assess the financial impact of the potential $350.5 million termination fee if the Merger fails to close under specific scenarios.
- PALSONIFY Commercialization: Monitor sequential revenue growth and payer reimbursement rates to validate the commercial trajectory post-launch.
- Atumelnant Clinical Data: Track the initiation and enrollment of the EQUILIBRIUM Phase 2/3 study for ADCS.
- Equity Dilution: Note that the January 2026 offering raised $380 million; verify if any further capital raises are planned pending the Merger outcome.